{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:25:42Z","timestamp":1794327942639,"version":"4.9.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Invasive fungal disease remains a major cause of morbidity and mortality among children with malignancies and those undergoing hematopoietic stem cell transplantation (HSCT). Real-world data that describe antifungal prescribing practices in pediatric hematology\u2013oncology units are very limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A national prospective observational study from June 2016 through December 2019 in 5 pediatric hematology\u2013oncology units and the single pediatric HSCT unit in Greece was conducted. The first 15 children per month admitted to these units who required initiation of new antifungal agents for prophylaxis or treatment were recorded. Demographics, presence of a central venous line, type of underlying disease, absolute neutrophil count on the first day of antifungal therapy, presence of invasive fungal disease, days of therapy, microbiologic findings and outcomes were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 1838 anti-infective courses, 737 (40.1%) involved antifungal agents. Antifungal use was predominantly prophylactic (47.6%) or empiric (50.7%), with targeted therapy accounting for only 1.5%. Prophylaxis was more common in the HSCT unit, whereas empiric therapy predominated in pediatric hematology\u2013oncology units. Fluconazole was the most frequently used prophylactic agent, followed by micafungin and voriconazole. Proven fungemia was uncommon;\n                      <jats:italic toggle=\"yes\">Candida albicans<\/jats:italic>\n                      was the most frequently isolated pathogen. Overall mortality was 1.8%, with slightly higher mortality among patients receiving antifungal therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Antifungal use in pediatric oncology and HSCT settings was extensive and heterogeneous, characterized by heavy reliance on prophylactic and empiric strategies and minimal targeted therapy. These findings support the need for structured antifungal stewardship programs to optimize antifungal exposure while preserving favorable outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005344","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:02:49Z","timestamp":1785211369000},"page":"1076-1079","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Antifungal Use in Pediatric Hematology\u2013Oncology and Bone Marrow Transplantation Units in Greece"],"prefix":"10.1097","volume":"45","author":[{"given":"Maria","family":"Kourti","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Third Department of Pediatrics, Aristotle University School of Medicine, Hippokration General Hospital"},{"name":"Children and Adolescent Hematology-Oncology Unit, Second Department of Pediatrics, Aristotle University School of Medicine, AHEPA General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8313-9141","authenticated-orcid":false,"given":"Loizos","family":"Petrikkos","sequence":"additional","affiliation":[{"name":"1Health Region of Attica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9881-451X","authenticated-orcid":false,"given":"Elias","family":"Iosifidis","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Third Department of Pediatrics, Aristotle University School of Medicine, Hippokration General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kopsidas","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Outcomes Research (CLEO)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Kourkouni","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Outcomes Research (CLEO)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kondylia","family":"Antoniadi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology-Oncology, Aghia Sophia Children\u2019s Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambrini","family":"Damianidou","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Kaisari","sequence":"additional","affiliation":[{"name":"Stem Cell Transplantation Unit, Aghia Sophia Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kontogeorgou","sequence":"additional","affiliation":[{"name":"First Department of Pediatrics, National and Kapodistrian University of Athens, Aghia Sophia Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smaragda","family":"Papachristidou","sequence":"additional","affiliation":[{"name":"Oncology Department, \u201cP & A Kyriakou\u201d Children\u2019s Hospital, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tragiannidis","sequence":"additional","affiliation":[{"name":"Children and Adolescent Hematology-Oncology Unit, Second Department of Pediatrics, Aristotle University School of Medicine, AHEPA General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroula","family":"Tsipou","sequence":"additional","affiliation":[{"name":"First Department of Pediatrics, National and Kapodistrian University of Athens, Aghia Sophia Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Doganis","sequence":"additional","affiliation":[{"name":"Oncology Department, \u201cP & A Kyriakou\u201d Children\u2019s Hospital, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Hatzipantelis","sequence":"additional","affiliation":[{"name":"Children and Adolescent Hematology-Oncology Unit, Second Department of Pediatrics, Aristotle University School of Medicine, AHEPA General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Kitra","sequence":"additional","affiliation":[{"name":"Stem Cell Transplantation Unit, Aghia Sophia Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Papakonstantinou","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9716-9264","authenticated-orcid":false,"given":"Sophia","family":"Polychronopoulou","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology-Oncology, Aghia Sophia Children\u2019s Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grammatiki-Christina","family":"Tsopela","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Outcomes Research (CLEO)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theoklis","family":"Zaoutis","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Outcomes Research (CLEO)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0202-364X","authenticated-orcid":false,"given":"Emmanuel","family":"Roilides","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Third Department of Pediatrics, Aristotle University School of Medicine, Hippokration General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"R1-20261110","doi-asserted-by":"crossref","first-page":"100132","DOI":"10.1016\/j.ejcped.2023.100132","article-title":"Infections in children and adolescents with hematological malignancies.","volume":"2","author":"Attarbaschi","year":"2023","journal-title":"EJC Paediatr Oncol"},{"key":"R2-20261110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11046-025-01011-y","article-title":"Antifungal prescription and stewardship in pediatrics.","volume":"190","author":"Evangelidis","year":"2025","journal-title":"Mycopathologia"},{"key":"R4-20261110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jhin.2018.07.032","article-title":"Establishing nationally representative central line-associated bloodstream infection surveillance data for paediatric patients in Greece.","volume":"101","author":"Kouni","year":"2019","journal-title":"J Hosp Infect"},{"key":"R5-20261110","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America.","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R6-20261110","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pbc.25335","article-title":"Core outcomes and definitions for pediatric fever and neutropenia research: a consensus statement from an international panel.","volume":"62","author":"Haeusler","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R7-20261110","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) consensus group.","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R8-20261110","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R9-20261110","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1097\/MPH.0000000000003070","article-title":"Antifungal use in immunocompromised children in Europe: a 12-week multicenter weekly point prevalence survey (CALYPSO).","volume":"47","author":"Chorafa","year":"2025","journal-title":"J Pediatr Hematol Oncol"},{"key":"R10-20261110","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1097\/INF.0000000000003402","article-title":"Pediatric antifungal prescribing patterns identify significant opportunities to rationalize antifungal use in children.","volume":"41","author":"Ferreras-Antol\u00edn","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20261110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12879-021-05774-9","article-title":"Antifungal stewardship in a tertiary care paediatric hospital: the PROAFUNGI study.","volume":"21","author":"Mendoza-Palomar","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R12-20261110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MPH.0000000000000926","article-title":"Voriconazole antifungal prophylaxis in children with malignancies: a nationwide study.","volume":"40","author":"Pana","year":"2018","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:01:30Z","timestamp":1794326490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005344","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"2026-02-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}